In this article, we will discuss Durvalumab (Warnings-21). So, let’s get started.
Hyperthyroidism: Immune-mediated hyperthyroidism occurred in 2.1% (39/1889) of patients receiving IMFINZI. Events resolved in 30 of the 39 patients and did not lead to permanent discontinuation of IMFINZI in any patients. Systemic corticosteroids were required in 9 patients (9/39) with immune- mediated hyperthyroidism, while 35 patients (35/39) required endocrine therapy.